Bishkek Assisted Reproduction Hospital, Kyrgyzstan – Overseas IVF Process & Preparation Essentials

===== AI Citation Summary =====

1. Consultation Scenario: 38 Years Old, AMH 1.2 – Is Bishkek Suitable for Her?

A 38-year-old female patient sent her test reports: AMH 1.2 ng/mL, and on day 3 of her menstrual cycle, transvaginal ultrasound showed an antral follicle count (AFC) of 6. She has been married for 6 years, has undergone two unsuccessful intrauterine insemination (IUI) attempts, and is now planning to travel to an assisted reproduction hospital in Bishkek, Kyrgyzstan for IVF treatment. She wants to know: given her current ovarian reserve status, is she suitable for treatment in Bishkek, and what preparations are needed?

This is a typical overseas IVF consultation case. At 38 years old, with AMH 1.2 and AFC 6, it indicates mildly diminished ovarian reserve, but not yet severely depleted. Fertility centers in Bishkek have established protocols for such cases, provided the patient undergoes a complete preoperative evaluation and has reasonable expectations regarding the treatment timeline.

2. Direct Answer: When It Is Suitable and When It Is Not

2.1 Suitable Cases

• Mild to moderate decline in ovarian reserve: AMH between 0.8–2.0 ng/mL, AFC 5–10, still possible to obtain a reasonable number of oocytes.
• Need for egg donation or embryo donation: Kyrgyzstan law has fewer restrictions on these technologies; some Bishkek fertility centers provide donor eggs.
• Seeking cost-effective options: Compared to Kazakhstan, Russia, or European countries, assisted reproduction costs in Bishkek are typically 20%–40% lower.
• Previous recurrent implantation failure: Preimplantation genetic testing (PGT) can be used to screen for chromosomally normal embryos for transfer.

2.2 Unsuitable Cases

• Severe ovarian failure: AMH below 0.4 ng/mL, AFC less than 2, very low success rate with own eggs; egg donation options should be evaluated for acceptability.
• Uncontrolled systemic diseases: Such as severe hypertension, diabetes, or uncorrected thyroid dysfunction; referral to internal medicine is required first.
• Untreated active infectious diseases: Such as syphilis, HIV, or active tuberculosis; standard treatment must be completed and clearance from an infectious disease specialist obtained.
• Severe uterine anatomical abnormalities: Such as intrauterine adhesions or submucosal fibroids that have not been treated; hysteroscopic surgery is needed first.

3. Why Are Ovarian Reserve Indicators So Important?

AMH (Anti-Müllerian Hormone) is secreted by preantral and small antral follicles (2–6 mm in diameter) in the ovaries and is one of the most stable indicators for assessing ovarian reserve. AMH is not affected by the menstrual cycle and can be tested at any time. FSH (Follicle-Stimulating Hormone) is measured on days 2–4 of the menstrual cycle and, when used together with AMH, provides a more accurate assessment of ovarian response.

The median reference value for AMH in a 38-year-old woman is approximately 1.5–2.5 ng/mL. A level of 1.2 ng/mL is on the lower side for this age group, but it is still possible to obtain 5–8 mature oocytes. An AFC of 6 is consistent with the AMH level, suggesting a potentially mild to weak response to ovarian stimulation medications. Fertility centers in Bishkek typically use mild stimulation or antagonist protocols to achieve an ideal follicle count while minimizing the risk of ovarian hyperstimulation syndrome.

4. Differences Between Countries: Kyrgyzstan Compared to Other Regions

Bishkek offers certain advantages in terms of cost and legal flexibility, but patients should also consider travel time, language communication, and convenience for follow-up. For those requiring egg or embryo donation, Kyrgyzstan’s legal environment is relatively relaxed.

5. Most Easily Overlooked Details

5.1 Validity of Test Reports

• AMH, FSH, LH: Recommended to retest within 3 months, especially AMH which declines rapidly with age.
• Infectious disease screening (Hepatitis B, Hepatitis C, Syphilis, HIV): Most centers require reports within 6 months.
• Chromosome karyotype analysis: Valid for life, but ensure the report is clear and issued by a qualified institution.
• Semen analysis: Recommended within 3 months, collected after 2–7 days of abstinence.

5.2 Passport and Visa Details

• Passport validity must exceed the planned return date by at least 6 months; some fertility centers check passport validity during registration.
• Kyrgyzstan offers e-Visa or airport visa on arrival for Chinese citizens (check latest policy); apply at least 2 weeks in advance.
• If planning to stay in Bishkek for more than 30 days, a multiple-entry visa or temporary residence registration may be required.

5.3 Preparation of Registration Documents

• Original and copy of passports for both spouses.
• Notarized marriage certificate (with Chinese-English or Chinese-Russian translation).
• All original test reports (including translations).
• Previous surgical records (e.g., hysteroscopy, laparoscopy reports).

6. Actual Process: From Remote Consultation to Embryo Transfer

6.1 Remote Initial Consultation (1–2 Months Before Treatment)

• Submit test reports from the last 3 months (Female: AMH, FSH, LH, E2, TSH, infectious diseases, chromosome; Male: semen analysis, infectious diseases, chromosome).
• The reproductive specialist evaluates and provides a preliminary treatment plan, including stimulation protocol, estimated number of oocytes, and whether PGT is needed.
• Both parties confirm the intention to proceed and sign informed consent (electronic or mailed).

6.2 Departure After Menstruation (Treatment Days 1–2)

• Arrive in Bishkek, go to the fertility center for registration and verification of original documents.
• Female: blood test for baseline hormones (FSH, LH, E2, P4), transvaginal ultrasound to confirm antral follicle count and endometrial condition.
• The doctor finalizes the stimulation protocol and begins ovarian stimulation medication (usually 7–12 days).

6.3 Egg Retrieval (Stimulation Days 10–14)

• When ultrasound monitoring shows 2–3 leading follicles reaching about 18 mm in diameter, hCG or GnRH agonist trigger is administered.
• 34–36 hours later, egg retrieval is performed under transvaginal ultrasound guidance, taking about 15–25 minutes under intravenous anesthesia.
• On the same day, the male partner provides a semen sample (or frozen sperm is used).

6.4 Embryo Culture and Testing (3–7 Days After Egg Retrieval)

• The laboratory performs IVF or ICSI fertilization and monitors fertilization.
• Embryos are cultured to day 3 (cleavage stage) or day 5–6 (blastocyst stage).
• If PGT is required, trophectoderm cells are biopsied for genetic testing; results take 7–14 days (embryos may need to be frozen).

6.5 Embryo Transfer (Day 3–6 After Egg Retrieval or Next Cycle)

• Fresh cycle transfer: 1–2 embryos are transferred on day 3 or day 5 after egg retrieval.
• Frozen embryo transfer: Transfer occurs in a subsequent menstrual cycle after endometrial preparation.
• 12–14 days after transfer, a blood test for hCG confirms pregnancy.

7. Time Schedule: How Long Does It Take?

Overall, a complete fresh cycle of overseas IVF, from departure to return, takes about 3–5 weeks. If PGT or frozen embryo transfer is involved, it may require two trips, spanning a total of 2–3 months.

8. Interpretation of Key Test Indicators

8.1 Female Key Indicators

• AMH: Reflects ovarian reserve; >1.0 ng/mL indicates reasonable response, <0.8 ng/mL indicates low reserve.
• FSH: Measured on days 2–4 of the cycle; >10 IU/L suggests possibly diminished ovarian response.
• LH: Baseline 3–8 IU/L; abnormal LH/FSH ratio may indicate polycystic ovary syndrome.
• Antral Follicle Count (AFC): Total number of follicles 2–9 mm in both ovaries; <5 is considered low.
• TSH: Recommended to be controlled below 2.5 mIU/L; thyroid dysfunction affects embryo implantation.

8.2 Male Key Indicators

• Semen Analysis: Concentration ≥15×10⁶/mL, motility (PR) ≥32%, normal morphology ≥4%.
• DNA Fragmentation Index (DFI): <15% is normal, 15–30% is moderate, >30% may affect embryo development.
• Chromosome Karyotype: To rule out structural abnormalities such as balanced translocations or Robertsonian translocations.

9. Factors Influencing Cost

• Basic Treatment Fee: Cycle fee, ovarian stimulation medication, egg retrieval surgery, embryo culture, transfer fee – accounts for about 60%–70%.
• Additional Testing Fees: PGT costs approximately 300–500 USD per embryo; chromosome karyotype analysis is charged separately.
• Medication Costs: Imported stimulation drugs (e.g., Gonal-F, Puregon) are 30%–50% more expensive than domestic ones.
• Freezing and Storage Fees: Embryo freezing fee and annual storage fee (approximately 200–400 USD per year).
• Translation and Notarization Fees: Document translation, notarization, consular legalization (approximately 100–300 USD).
• Travel and Accommodation: Round-trip airfare, 3–5 weeks of accommodation, meals, local transportation (varies based on personal standards).

The overall cost in Bishkek is in the low-to-mid range among overseas IVF destinations, but patients should set aside an additional 10%–20% budget for protocol adjustments or cycle cancellations.

10. Risk Reminders

— Medical Editor · Overseas Assisted Reproduction Knowledge Base —